Rajib Chandra Das,

Poster Author Of 1 e-Poster

Author Of 1 Presentation

IMPACT OF 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV-10) ON PNEUMONIA HOSPITALIZATION RATE AMONG BANGLADESHI CHILDREN (ID 1134)

Abstract

Background

Bangladesh introduced PCV-10 in March 2015 with a 3+0 schedule. We assessed impact of PCV-10 on pneumonia and severe pneumonia among children <5 years.

Methods

Children <5 years were enrolled following WHO’s Invasive Bacterial Vaccine Preventable Disease surveillance criteria. January 2011 to March 2015 was considered as baseline and April 2015 to June 2019 as post-PCV era. PCV-10 impact was measured based on hospitalization rate (adjusted with all hospitalized patients) of pneumonia and severe pneumonia using (I) WHO case definitions and (II) physician’s diagnosis.

Results

Analysis using WHO’s case definition didn’t show any significant changes in pneumonia admissions among those <5 years or 3-23 months. Similarly, no impact was noted for admissions of physician-diagnosed pneumonia. However, physician-diagnosed severe pneumonia episodes decreased 82% (95% CI: 78.9%-84.2%) from 4.5%-0.8% among those <5 years and 76.1% (95% CI 69.8%-81.2%) from 4.4 -1% among children 3-23 months.

Conclusions

The lack of significant change for WHO-defined pneumonia and severe pneumonia or physician-diagnosed pneumonia may be due to a lack of specificity in the definitions, including many illnesses not caused by pneumococcal infection. Reduction in severe pneumonia admissions (among which more cases are expected to be bacterial), suggests a role of PCV-10 in reduction of pneumococcal pneumonia.

Hide